GH Research (NASDAQ:GHRS) Rating Increased to Hold at Wall Street Zen

GH Research (NASDAQ:GHRS - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.

GHRS has been the subject of a number of other reports. Cantor Fitzgerald initiated coverage on shares of GH Research in a research note on Wednesday, June 4th. They issued an "overweight" rating and a $25.00 price objective for the company. Guggenheim lowered their price target on shares of GH Research from $32.00 to $29.00 and set a "buy" rating for the company in a research report on Friday, May 9th. JMP Securities restated a "market outperform" rating and set a $39.00 target price on shares of GH Research in a report on Tuesday, June 24th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of GH Research in a report on Friday, May 9th. Finally, Royal Bank Of Canada assumed coverage on GH Research in a research note on Friday, March 7th. They set an "outperform" rating and a $31.00 price objective for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $32.00.

GH Research Stock Performance

Shares of NASDAQ GHRS opened at $14.91 on Friday. The firm has a market capitalization of $775.77 million, a price-to-earnings ratio of -18.87 and a beta of 0.96. The stock has a 50 day moving average price of $11.82 and a 200 day moving average price of $10.82. GH Research has a 52-week low of $6.00 and a 52-week high of $20.50.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.42. Analysts forecast that GH Research will post -0.8 earnings per share for the current year.

Institutional Trading of GH Research

Hedge funds and other institutional investors have recently made changes to their positions in the business. Two Sigma Investments LP purchased a new stake in shares of GH Research during the 4th quarter valued at $117,000. Millennium Management LLC purchased a new stake in GH Research in the fourth quarter valued at about $145,000. BNP Paribas Financial Markets purchased a new stake in GH Research in the fourth quarter valued at about $44,000. Northern Trust Corp raised its position in shares of GH Research by 26.8% in the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock valued at $286,000 after purchasing an additional 8,641 shares during the last quarter. Finally, Woodline Partners LP raised its position in shares of GH Research by 112.0% in the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company's stock valued at $553,000 after purchasing an additional 41,711 shares during the last quarter. Hedge funds and other institutional investors own 56.90% of the company's stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.